Antitrust and Consumer Protection
Competition: Winter 2017-18, Vol. 27, No. 1
Content
- Antitrust's Hidden Hook In Drug Price Increases
- Causation Principles In Pharmaceutical Antitrust Litigation
- Certificates of Public Advantage: Bypassing the Ftc In Healthcare Mergers?
- Chair's Column
- Digital Health Privacy: Old Laws Meet New Technologies
- Empirical Evidence of Drug Companies Using Citizen Petitions To Hold Off Competition
- Masthead
- Rethinking Healthcare Data Breach Litigation
- The Efficiencies Defenestration: Are Regulators Throwing Valid Healthcare Efficiencies Out the Window?
- The Proximate Cause Requirement In Private Reverse Payment Antitrust Litigation
- Uncertainty and Scientific Complexity: An Introduction To Economic Forces That Drive Current Debates In Healthcare Antitrust
- What Past Agency Actions Say About Complexity In Merger Remedies, With An Application To Generic Drug Divestitures
- Where Art Thou, Efficiencies? the Uncertain Role of Efficiencies In Merger Review
- Editor's Note
EDITOR’S NOTE
Anna Fabish
O’Melveny & Myers LLP
Los Angeles, CA
Competition and privacy law issues in the healthcare and pharmaceutical industries are constantly making headlines—and for good reason. The intersection of healthcare/ pharmaceutical regulation and policy with competition, privacy, and intellectual property law is generating a vast universe of intriguing questions. And if the amount of litigation and enforcement efforts in the United States and abroad is any indication, that universe is only growing. There is simply no escaping that hospitals and pharmacies are the foremost frontier for competition and privacy law issues today.